Paolini John F.

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
12
Insider Sells Sum
$5.85M

Insider Activity of Paolini John F.

According to the SEC Form 4 filings, Paolini John F., being in a position of

  1. CHIEF MEDICAL OFFICER at Kiniksa Pharmaceuticals, Ltd.,
    оver the last 12 months, has bought 0 shares, and sold 140292 shares for $3.29M,
    over all time since 2020-02-13, has bought 0 shares, and sold 313598 shares for $5.85M.

The largest sale of all time was on 2024-09-03 and amounted to 60692 shares of Kiniksa Pharmaceuticals, Ltd. for $1.58M.

Biography of Paolini John F.

No biography is available at this moment.

2024-09-03SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
60,692
0.0855%
$26.12$1.58M-3.88%
2024-07-23SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
22,000
0.0311%
$26.32$578,966-1.54%
2024-03-01SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
18,844
0.0269%
$21.77$410,234-8.07%
2024-02-27SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
10,156
0.0145%
$21.03$213,581-4.26%
2023-12-07SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
28,600
0.0801%
$17.65$504,758+11.07%
2023-09-05SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
400
0.0006%
$17.53$7,012+9.91%
2023-07-25SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
29,000
0.0409%
$19.14$555,160-6.57%
2022-11-07SaleKiniksa Pharmaceuticals, Ltd.
KNSA
CHIEF MEDICAL OFFICER
56,714
0.0814%
$15.18$860,919-1.54%
2020-02-20SaleKiniksa Pharmaceuticals, Ltd.
KNSA
SVP & Chief Medical Officer
19,606
0.0358%
$18.96$371,665+0.24%
2020-02-19SaleKiniksa Pharmaceuticals, Ltd.
KNSA
SVP & Chief Medical Officer
44,954
0.0491%
$11.04$496,067+2.79%
2020-02-14SaleKiniksa Pharmaceuticals, Ltd.
KNSA
SVP & Chief Medical Officer
2,078
0.004%
$18.33$38,090+8.02%
2020-02-13SaleKiniksa Pharmaceuticals, Ltd.
KNSA
SVP & Chief Medical Officer
20,554
0.0225%
$11.04$227,019+2.49%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.